Preparation and antileukemic activity of epirubicin conjugate with chitosan

Simple item page
dc.contributor.authorTodorova N.
dc.contributor.authorManeva K.
dc.contributor.authorTodorov D.
dc.date.accessioned2024-07-10T14:27:04Z
dc.date.accessioned2024-07-10T14:48:39Z
dc.date.available2024-07-10T14:27:04Z
dc.date.available2024-07-10T14:48:39Z
dc.date.issued2004-01-01
dc.description.abstractCondensation of the antitumor antibiotic epirubicin with oxidized chitosan provided a new conjugated antibiotic. The resultant compound was characterized by IR and UV-Vis-spectra with support the conjugate structure. The amount of epirubicin bound to the matrix was 22.5% or 315 epirubicin residues. The biological activity of epirubicin-chitosan conjugate showed an antibacterial action against Bacillus Subtilis AT 6633 on the level of the initial antibiotic. The ascetic form of lymphocytic leukemia P 388 and lymphoid leukemia L1210 (transplantation dose 106 tumor cells) in hybrid mice BDF1 was used as leukemic model. Antileukemic activity of the studied conjugate was found with a clear “dose-effect” correlation. The criterion “increase of live span” is maximally 342.1% in P338 and 371.5% in L1210 for the conjugate in comparation with maximally 179.0% in P388 and 197.2% in L1210 for the free epirubicin. The conjugate showed lower toxicity and higher therapeutic index. © 2004 Taylor and Francis Group, LLC.
dc.identifier.doi10.1080/13102818.2004.10817140
dc.identifier.issn1310-2818
dc.identifier.scopusSCOPUS_ID:85023994245en
dc.identifier.urihttps://rlib.uctm.edu/handle/123456789/436
dc.language.isoen
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85023994245&origin=inward
dc.titlePreparation and antileukemic activity of epirubicin conjugate with chitosan
dc.typeArticle
oaire.citation.issue3
oaire.citation.volume18
Files
Collections
Articles